All In Biotech

Drug Trial Radar · NCT06764771

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

437

Planned (sponsor's estimate)

Start

Mar 25, 2025

Primary completion

Oct 15, 2027

Study completion Oct 15, 2027

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jan 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.

Conditions

  • Advanced Malignant Tumors

Interventions

  • BMS-986488Drug

    Specified dose on specified days

  • AdagrasibDrug

    Specified dose on specified days

  • CetuximabDrug

    Specified dose on specified days

  • NivolumabDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events (AEs)Time frame: Until the end of the Safety Follow-up period (up to approximately 100 days after last dose)
  2. Number of participants with Serious AEs (SAEs)Time frame: Until the end of the Safety Follow-up period (up to approximately 100 days after last dose)
  3. Number of participants with AEs meeting protocol-defined Dose-Limiting Toxicity (DLT) criteriaTime frame: From first dose of study treatment until end of cycle 1 (1 Cycle = 28 Days)
  4. Number of participants with AEs leading to discontinuationTime frame: Until the end of the Safety Follow-up period (up to approximately 100 days after last dose)
  5. Number of deathsTime frame: From time of informed consent up to 52 weeks after end of treatment visit

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Local Institution - 0020

    Allentown, Pennsylvania · Active not recruiting

  • The West Clinic, PLLC dba West Cancer Center

    Germantown, Tennessee · Recruiting

  • Local Institution - 0025

    Dallas, Texas · Withdrawn

  • Local Institution - 0031

    Brisbane, Queensland, Australia · Active not recruiting

  • BC Cancer Vancouver

    Vancouver, British Columbia, Canada · Recruiting

  • Local Institution - 0015

    Montreal, Quebec, Canada · Not yet recruiting

  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus

    Québec, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.